DOCSLIB.ORG

Gynecologic and Obstetric Pathology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gynecologic and Obstetric Pathology ANNUAL MEETING ABSTRACTS 273A Design: From January 2011 to August 2013, 162 patients underwent robotic laparoscopic radical prostatectomy for clinically localized prostatic carcinoma at our institution. Gynecologic and Obstetric Pathology Periprostatic fat pads, yielded during defatting of the prostate, were dissected and sent to pathology for histopathologic examination in 133 cases. Clinical and pathological 1128 Recurrent Grade I, Stage Ia Endometrioid Carcinomas of the Uterus: staging was recorded according to the 2009 American Joint Committee on Cancer Analysis of Pathology and Correlation with Clinical Data (AJCC) criterion. SN Agoff. Virginia Mason Medical Center, Seattle, WA. Results: Of 133 patients whose periprostatic fat was examined, 32 (24%) patients had Background: Low-grade and low-stage endometrioid carcinoma of the uterus is thought lymph nodes in the periprostatic fat pads. Metastatic prostatic carcinoma to periprostatic to have an excellent prognosis in the vast majority of patients. However, despite the lack lymph nodes was detected in 5 individuals (3.8%). All 32 patients had bilateral pelvic of myometrial invasion or superfi cial invasion, some patients develop recurrent disease, lymphadenectomy. 3 of the 5 patients with positive periprostatic lymph nodes had no often in the vaginal apex. There is limited literature on these tumors, but recent analyses metastasis in pelvic lymph nodes, thereby upstaging 3 cases from T3N0 to T3N1. No have implicated the pattern of myoinvasion as a prognostic factor. The emphasis of relationship exists between the presences of periprostatic LNs and prostate weight, the current study is non-invasive or stage Ia, grade I endometrioid adenocarcinomas. patient age, pathological staging or Gleason score. When compared to cases with Design: The pathology data base at Virginia Mason Medical Center (VMMC) was tumor free periprostatic LNs, the tumor in cases with metastatic periprostatic LNs searched for cases of grade I endometrioid carcinoma from 1998 to 2012, along with has following features: 1) higher postoperative Gleason score (P=0.01); 2) higher prior biopsy diagnosis. Cases with concurrent ovarian and carcinoma were excluded pathological staging (p=0.001); 3) higher rate of seminal vesicle invasion (p=0.01); as were cases with 50% or > myometrial invasion. Pathological and clinical data was 4) higher rate of extracapsular invasion (p=0.00001); higher rate of positive surgical collected. Histological evaluation was performed, when possible, on either the original resection margin (P=0.001). biopsy, hysterectomy and/or follow-up biopsies. Pt with tumor free LNs in Pt with metastatic LNs in Results: At VMMC, there were 243 cases of grade I stage Ia endometrioid P value periprostatic fat periprostatic fat adenocarcinoma. Of these, 85 had lymph node dissections, 37 had omental and/or Number of Patient 27 5 peritoneal biopsies. Peritoneal washes were performed on all patients and 12 were Age 0.79 positive for tumor. Angiolymphatic invasion was present in 9 patients, lower uterine mean 60 59.2 range 49-75 50-62 segment involvement was present in 5 (3 -epithelial only, and 2 - invasive) and prostate weight 0.33 endocervical gland involvement in 2. From these, only 9 patients experienced recurrent mean 45.1 55.6 disease (4%), the majority in the vaginal cuff (67%). Non-myoinvasive tumors accounted range 23-123 40-75 for 5 cases and 4 patients had superfi cial (<50%) invasion. Angiolymphatic invasion postoperative Gleason 0.01 score was present in 2 patients, lower uterine segment invasion in one and one patient had a 3+3 7 0 positive peritoneal wash. None of the patients had post-hysterectomy treatment. After 3+4 12 0 recurrence, 7 patients had pelvic and vaginal radiation therapy, 2 chemotherapy (1 4+3 4 4 with radiation); 1 has not received therapy yet. Average follow-up time was 20 months >4+3 4 1 Seminal vesicle (39 to 8 months), 2 were lost to followup. Six patients had NED, 1 died with disease. 6 4 0.01 invasion (+) Conclusions: The majority of patients with grade I and stage Ia endometrial Extracapsular 2 5 0.00001 adenocarcinoma have an excellent outcome with no treatment. Rare cases have invasion (+) recurrence of disease. Treatment after recurrence in our study resulted in good clinical Surgical resection 7 5 0.001 margin (+) outcomes for patients where long term followup was available. Further analysis is need Pathology stage 0.001 in order to determine why some patients recur after surgery while the majority do not. pT2 22 0 pT3a 2 1 pT3b 3 4 1129 Uterine Serous and FIGO 3 Endometrioid Carcinomas: A Multi- Conclusions: Despite the relative low incidence of positive periprostatic lymph node, Institutional Comparative Study of 335 Cases routine pathological work up of periprostatic fat pads should be performed to guarantee QF Ahmed, YR Hussein, J Bennett, K Van De Vijver, S Thomas, B Alosh, E Abdulfatah, adequate lymph node staging. D Schultz, S Bandyopadhyay, R Soslow, E Oliva, R Ali-Fehmi. WSU, Detroit, MI; Henry Ford Hospital, Detroit, MI; MGH, Boston, MA; MSKCC, New York, NY. Background: Although uterine serous carcinoma (USC) and FIGO grade 3 endometrioid 1127 Immunoexpression of Napsin A in Renal Neoplasms carcinoma(E3C) constitute a minority of all endometrial carcinomas, they account for B Zhu, SM Rohan, D DeFrias, X Lin. University of Illinois at Chicago, Chicago, IL; a disproportionate number of deaths. The study aimed to compare clinicopathologic Northwestern University, Chicago, IL. features and outcome of USC E3C. Background: Immunohistochemistry (IHC) for Napsin A has been widely used to Design: 335 endometrial carcinomas were identifi ed from 4 institutions. Only E3C support a diagnosis of lung adenocarcinoma with high sensitivity (93.9%). Previous and USC reviewed and agreed on by 2 GYN pathologists(average of 4 slides/case) reports have stated that Napsin A is also highly specifi c for lung adenocarcinoma (up to using WHO criteria were included in the study. 99 E3C and 167 USC were included 94.7%). However, a recent report demonstrated that Napsin A is expressed in papillary in the fi nal cohort. Clinicopathologic variables were analyzed, including patient renal cell carcinoma (RCC). In this study, we evaluated the immunoexpression of demographics, tumor type, myometrial invasion, lymphovascular invasion(LVI), Napsin A in renal neoplasms. cervical involvement(CI), lymph node(LN) status, FIGO stage, recurrence overall Design: Duplicate tissue microarrays (TMA) of 159 surgically excised renal neoplasms survival. of various types were constructed. IHC for Napsin A was performed on TMAs with Results: Median age of patients with E3C and USC was 61 69 yrs, respectively. Outer appropriate positive and negative controls. Tumors with more than 10% cells staining half myometrial invasion was identifi ed more often in E3C compared to USC(p=.001). positive for Napsin A were considered as immunoreactive. Absence of myometrial invasion was seen more frequently in USC(p=.002). CI(p=.015), Results: See Table 1. metastases to fallopian tubes(p=.001) recurrence(p=.001) were seen more frequently Table 1. Expression of Napsin A in renal neoplasms. in USC. Although there was no signifi cant difference in LVI,a higher number of positive Neoplasm No. Napsin A (%) LNs was identifi ed in E3C(p=.001). Omental involvement was seen more in USC than Acquired cystic disease associated RCC 2 100.0 Chromophobe RCC 45 11.1 E3C(p=.05). Early FIGO stage(I-II) was seen more frequently in E3C, whereas more Clear cell RCC 23 43.5 cases of advanced stage (stage IV) were seen in USC(p=.009).There was no statistical Clear cell papillary RCC 19 47.4 difference in overall survival between the 2 cohorts matched by stage(p=.264) Metanephric adenoma 3 100.0 Mucinous tubular and spindle cell carcinoma 1 0.0 Oncocytoma 23 56.5 Papillary RCC 37 83.8 TFE/MITF RCC 1 0.0 Urothelial carcinoma 6 0.0 Conclusions: Napsin A is expressed in various types of renal neoplasms with sensitivity up to 100.0%. It is, sometimes, diffi cult to distinguish oncocytoma from chromophobe RCC on fi ne needle aspiration and/or needle core biopsy of a renal tumor. IHC for Napsin A may be useful in distinguishing oncocytoma from chromophobe RCC with positive labeling favoring oncocytoma. Based on our results, Napsin A is not specifi c for lung adenocarcinoma. When an metastatic carcinoma of unknown primary is positive for Napsin A, the differential diagnosis should include tumors of both renal and lung origin. 274A ANNUAL MEETING ABSTRACTS Clinicopathologic features 1131 Impact of Histological Subtype in Early Stage Cervical Cancer: A E3C,n=99(%) USC,n=167(%) p value Multi-Instituitional Study Median Age 61y 69y B Alosh, I Alvarado-Cabrero, I Winer, S Thomas, D Schultz, R Ali-Fehmi. WSU, Detroit, Race* .121 MI; Mexican Oncology Hospital, Mexico, Mexico. AA 18(42.9) 64(55.7) Other 24(57.1) 51(44.5) Background: Cervical adenocarcinomas(ADC) are viewed as more aggressive than cervical squamous cell carcinomas(SCC). This study aimed to determine the impact Myometrial Invasion .002 of SCC vs. ADC in early stage(ES) cervical cancer. Yes 90(90.9) 126(75.4) Design: 283 patients(pts) diagnosed with ES (IA1-IB2) cervical ADC(132) No 9(9.1) 41(24.6) SCC(151) during 2000-2010 from 2 inner city hospitals (Mexico and Detroit) was Depth of Invasion* .001 included.Age,stage,tumor size,depth of invasion,lymphovascular invasion (LVI),lymph None 0(0) 41(24.6) node status (LNS),recurrence rate(RR) overall survival(OS) were analyzed.GYN Outer half
Load more

Recommended publications
  • Phenacetin Acts As a Weak Genotoxic Compound Preferentially in the Kidney of DNA Repair Deficient Xpa Mice
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis Volume 596, Issues 1-2 , 11 April 2006, Pages 143-150 doi:10.1016/j.mrfmmm.2005.12.011 Copyright © 2006 Elsevier B.V. All rights reserved. Phenacetin acts as a weak genotoxic compound preferentially in the kidney of DNA repair deficient Xpa mice Mirjam Luijtena,*, Ewoud N. Speksnijdera, Niels van Alphena, Anja W estermana, Siem H. Heisterkampb, Jan van Benthema, Coen F. van Kreijla, Rudolf B. Beemsa and Harry van Steega aLaboratory of Toxicology, Pathology and Genetics, National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands bCentre for Information Technology and Methodology, National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands Abstract Chronic use of phenacetin-containing analgesics has been associated with the development of renal cancer. To establish genotoxicity as a possible cause for the carcinogenic effect of phenacetin, we exposed wild type and DNA repair deficient XpaÞ/Þ and XpaÞ/Þ/Trp53+/Þ mice (further referred as Xpa and Xpa/p53 mice, respectively), carrying a reporter lacZ gene, to 0.75% (w/w) phenacetin mixed in feed. Xpa mice completely lack the nucleotide excision repair pathway, and as such they are sensitive to some classes of genotoxic compounds. Phenacetin exposure induced a significant increase of lacZ mutations in the kidney of both Xpa and Xpa/p53 mice. A minor response was found in liver, whereas no lacZ mutation induction was observed in the spleen of these animals. Interestingly, the observed phenacetin-induced mutant frequencies were higher in male than those found in female mice.
    [Show full text]
  • "General Pathology"
    ,, ., 1312.. CALIFORNIA TUMOR TISSUE REGISTRY "GENERAL PATHOLOGY" Study Cases, Subscription B October 1998 California Tumor Tissue Registry c/o: Department of l'nthology and Ruman Anatomy Loma Lindn Universily School'oflV.lcdicine 11021 Campus Avenue, AH 335 Lomn Linda, California 92350 (909) 824-4788 FAX: (909) 478-4188 E-mail: cU [email protected] CONTRIBUTOR: Philip G. R obinson, M.D. CASE NO. 1 - OcrOBER 1998 Boynton Beach, FL TISSUE FROM: Stomach ACCESSION #28434 CLINICAL ABSTRACT: This 67-year-old female was thought to have a pancreatic mass, but at surgery was found to have a nodule within the gastric wall. GROSS PATHOLOGY: The specimen consisted of a 5.0 x 5.5 x 4.5 em fragment of gray tissue. The cut surface was pale tan, coarsely lobular with cystic degeneration. SPECIAL STUDIES: Keratin negative Desmin negative Actin negative S-100 negative CD-34 trace to 1+ positive in stromal cells (background vasculature positive throughout) CONTRIBUTOR: Mar k J anssen, M.D. CASE NO. 2 - ocrOBER 1998 Anaheim, CA TISSUE FROM: Bladder ACCESSION #28350 CLINICAL ABSTRACT: This 54-year-old male was found to have a large rumor in his bladder. GROSS PATHOLOGY: The specimen consisted of a TUR of urinary bladder tissue, forming a 7.5 x 7. 5 x 1.5 em aggregate. SPECIAL STUDfES: C)1okeratin focally positive Vimentin highly positive MSA,Desmin faint positivity CONTRIBUTOR: Howard Otto, M.D. CASE NO.3 - OCTOBER 1998 Cheboygan, Ml TISSUE FROM: Appendix ACCESSION #28447 CLINICAL ABSTRACT: This 73-year-old female presented with acute appendicitis and at surgery was felt to have a periappendiceal abscess.
    [Show full text]
  • Life Science Journal, 2011;8(4)
    Life Science Journal, 2011;8(4) http://www.lifesciencesite.com Histopathological and Immunohistochemical Studies on the Adrenal Medullary Tumors in Egyptian Patients Samia, M. Sanad1, Mahmoud, A. El-Baz2, Omar, I. Ghonemy3 and Hassan, F. Abo El-Nazar4 1Zoology Department, Faculty of Science, Zagazig University, Egypt 2Pathology Department, Faculty of Medicine, Mansoura University, Egypt 3Zoology Department, Faculty of Science, Benha University, Egypt 4Urology and Nephrology Center, Mansoura University, Egypt [email protected] Abstract: The present study provides guide lines for the diagnosis of adrenal medullary tumors in Egyptian patients. This retrospective study included, 73 cases of adrenal medullary tumors (39 pheochromocytoma, 13 neuroblastoma, 12 ganglioneuroblastoma and 9 ganglioneuroma) admitted to Mansoura Urology and Nephrology Center, Egypt.. All tumors were studied histologically and immunohistochemically. In pheochromocytomas, 33 patients became normal after 24 hours, the other 6 died from distant metastases. 6 patients with neuroblastoma and ganglioneuroblastoma were still living after adrenalectomy, while the other 19 patients received chemotherapy and were non-living after 24 months. Nine patients with ganglioneuroma were still living after adrenalectomy. All prepared slides were stained with periodic-acid Schiff’ reaction (PAS) and reticulin stains. Hyaline globules which were (PAS) positive were pheochromocytomas, while, they were not detected in neuroblastoma groups. All tumors were positive for reticulin stain. All cases of adrenal medulalry tumors were examined immunohistochemically using antibodies against chromogranin A, S-100 protein and neuron-specific enolase . Chromogranin A was expressed in all cases (39/39) pheochromocytoma, 5/13 neuroblastoma, 7/12 ganglioneuroblastoma and 7/9 ganglioneuroma. S-100 protein was expressed in 32/39 pheochromocytoma, 9/13 neuroblastomas, and all cases of ganglioneuroblastoma and ganglioneuroma.
    [Show full text]
  • Endometrioid Carcinoma
    Ovarian Cancer Endometrioid Carcinoma What is an Ovarian What characterizes Endometrioid Tumor? Ovarian Endometrioid Endometrioid tumors make up Carcinoma? about 2 to 4 percent of all ovar- Ovarian cancer often does not Definition of ian tumors and most of them present clear physical symptoms. Terms (about 80 percent) are malignant, Some signs of ovarian cancer representing 10 to 20 percent of include persistent (more than two Endometrial: all ovarian carcinomas. In some weeks) pelvic or abdominal pain Excessive growth of cases, endometrioid carcinomas of or discomfort; bloatedness, gas, cells in the endome- the ovary appear synchronously nausea and indigestion; vaginal trium, the tissue that with an endometrial carcinoma bleeding; frequent or urgent uri- lines the uterus. (epithelial cancer of the uterus) nation with and/or endometriosis (presence of no infection; Epithelial: Relating endometrial tissue outside unexplained to the epithelium, the uterus). weight gain tissue that lines the Ovarian Endometrioid Carcino- or loss; fa- internal surfaces of mas are the second most common tigue; and body cavities or ex- ternal body surfaces type of epithelial ovarian can- changes in of some organs, cer, which is the most common bowel habits. such as the ovary. ovarian cancer. According to the If you have American Cancer Society, ovar- a known his- ian cancer accounts for 6 percent tory of endo- Ovarian Endometri- Malignant: Cancer- of all cancers among women. The metriosis involving the ovary and oid Carcinoma often ous and capable of fi ve-year survival rate for women there is a change in the intensity does not present spreading. with advanced ovarian cancer is or type of symptoms that you are clear symptoms.
    [Show full text]
  • Tumors of the Uterus and Ovaries
    CALIFORNIA TUMOR TISSUE REGISTRY 104th SEMI-ANNUAL CANCER SEMINAR ON TUMORS OF THE UTERUS AND OVARIES CASE HISTORIES PRELECTOR: Fattaneh A. Tavassoll, M.D. Chairperson, GYN and Breast Pathology Armed Forces Institute of Pathology Washington, D.C. June 7, 1998 Westin South Coast Plaza Costa Mesa, California CHAIRMAN: Mark Janssen, M.D. Professor of Pathology Kaiser Pennanente Medical Center Anaheim, California CASE HISTORIES 104ru SEMI-ANNUAL SEMINAR CASE #t- ACC. 2S232 A 48-year-old, gravida 3, P.ilra 3, female on oral contraceptives presented with dysmenorrhea and amenorrhea of three months duration. Initial treatment included Provera and oral contraceptives. Pelvic ultrasound lev~aled a 7 x 5 em right ovarian cyst and a possible small uterine fibroid. Six months later, she returned with a large malodorous mass protruQing through the cervix <;>fan enlarged uterus. The 550 gram uterine specimen was 13 x 13 x 6 em. The myometrium was 4 em thick. A 8 x 6 em polypoid, pedunculated mass protruded through the cervix. The cut surface of the mass was partially hemorrhagic, surrounded by light tan soft tissue. (Contributed by David Seligson, M.D.) CASE #2- ACC. 24934 A 70-year-old female presented with vaginal bleeding of recent onset. A total abdominal hysterectomy and bilaterl!] salpingo-oophorectomx were performed. The 8 x 9 x 4 em uterus was symmetrically enlarged. The ·endometrial cavity was dilated by a 4.5 x 3.0 x4.0 em polypoid mass composed of loculated, somewhat mucoid tissue. Sections through the broad stalk revealed only superficial attachment to the myometrium, without obvious invasion.
    [Show full text]
  • RHCL 2019 Price List
    University of Texas MD Anderson Cancer Center Research Histology Core Laboratory Service Price List Service Provided Service Fee BONE SECTION Bone Section $6.50 per slide Additional bone section same slide $0.75 each section FROZEN SECTIONING Frozen Block Mount $4.50 each Frozen section $5.75 per slide Additional frozen sections on same slide + $0.75 per section* Additional frozen sections on same slide from additional blocks/map instructions + $1.00 per section* Cryomold $1.00 each OCT-Mold $3.00 each H&E STAINING H&E (-) Non Plus Slide $4.50 per slide H&E (+) Plus Slide $5.25 per slide H&E Stain Only $3.75 per slide H&E Stain Only (Plastic) on (+) slide $7.75 per slide H&E Stain (Manual) $8.00 per slide H&E Stain (Micron Interval) $6.25 each H&E Stain (Microdissection) $5.50 per slide Hematoxylin or Eosin Only $3.75per slide Additional H&E section on same slide +$0.50 per section * Additional H&E sections on same slide from additional blocks/map instructions +$1.00 per section* Deparaffinization $2.00 each IHC STAINING Immuno Manual Stain $35.00 per slide Immuno Stain $31.25 per slide Immuno Stain (Investigator AB) $25.00 per slide Immuno Stain (Plastic) $38.25 per slide Immuno Stain (Plastic Investigator AB) $35.25 per slide Immuno Stain (Manual) $28.00 per slide Immuno Stain – IHC $28.00 per slide Immuno Control Tissue $5.50 per slide Additional Titers $65.00 each Assay Development $468.75 each Fluorescent Counter Stain $15.00 per slide IMAGE ANALYSIS Scan Scope 20X (1-50) $8.00 per slide Scan Scope 20X (51-150) $7.00 per slide Scan
    [Show full text]
  • Molecular Reprogramming in Tomato Pollen During Development And
    Molecular reprogramming in tomato pollen during development and heat stress Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften vorgelegt beim Fachbereich Biowissenschaften (FB15) der Goethe-Universität Frankfurt am Main von Mario Keller geboren in Frankfurt am Main (Hessen) Frankfurt am Main 2018 (D30) Vom Fachbereich Biowissenschaften (FB15) der Goethe-Universität als Dissertation angenommen. Dekan: Prof. Dr. Sven Klimpel Gutachter: Prof. Dr. Enrico Schleiff, Jun. Prof. Dr. Michaela Müller-McNicoll Datum der Disputation: 25.03.2019 Index of contents Index of contents Index of contents ....................................................................................................................................... i Index of figures ........................................................................................................................................ iii Index of tables ......................................................................................................................................... iv Index of supplemental material ................................................................................................................ v Index of supplemental figures ............................................................................................................... v Index of supplemental tables ................................................................................................................ v Abbreviations ..........................................................................................................................................
    [Show full text]
  • Morphological Study of Ovarian Tumors with Special Reference to Germ Cell Tumors
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 14, Issue 1 Ver. VI (Jan. 2015), PP 55-60 www.iosrjournals.org Morphological Study of Ovarian Tumors with Special Reference to Germ Cell Tumors Dr. Kakumanu Nageswara Rao M.D (Path)1 Dr. Muthe Koteswari M.D (Path)2 Dr. Chaganti Padmavathi Devi MD, DCP3 Dr. Garikapati Sailabala MD(Path) 4 Dr. Ramya Katta MBBS5 1,2 Assistant Professor, Department of Pathology,Guntur Medical College, Guntur, A.P, India 3,4 Professor Department of Pathology, Guntur Medical College, Guntur, A.P, India Junior Resident Department of Pathology, Guntur Medical College, Guntur, A.P, India Abstract: Introduction: The study includes the morphological and histological aspects of the common tumors and also rare and uncommon ovarian tumors, with clinical manifestation, morphological and histopathological appearances. Material and Methods: Statistical incidence of ovarian tumors from 2001 to 2004 was taken. Specimens were processed routinely and sections, from representative sites, stained with hematoxylin and eosin were studied. Special stains like PAS, Vangieson, Reticulin and Alcian blue were done in special cases. Results: A total number of 150 ovarian tumors received from 2001 to 2004 have been studied. Of them 88 are benign tumors, 3 are borderline tumors & 59 are malignant tumors. Out of 150 ovarian tumors 122 were surface epithelial tumors, 9 were sex cord stromal tumors, 16 were germ cell tumors and 3 were metastatic tumors. Discussion: Ovary is the third most common site of primary malignancy in female genital tract and accounts for 6% of all cancers in females.
    [Show full text]
  • Renal Pyelocalyceal Squamous Cell Carcinoma in a Patient with An
    Güler et al. Journal of Medical Case Reports (2019) 13:154 https://doi.org/10.1186/s13256-019-2090-z CASEREPORT Open Access Renal pyelocalyceal squamous cell carcinoma in a patient with an ectopic kidney presenting with chronic pyelonephritis: a case report Yavuz Güler1*, Burak Üçpınar2 and Akif Erbin2 Abstract Background: Until now, few cases of pelvis squamous cell carcinoma in various renal anomalies have been reported. To our knowledge, primary squamous cell carcinoma arising from a pelvic ectopic kidney has never been described. In this report, we describe a case of renal pyelocalyceal squamous cell carcinoma in a patient with an ectopic kidney presenting with chronic pyelonephritis. Case summary: A 73-year-old Caucasian woman presented to our hospital with pyelonephritis symptoms. Abdominopelvic computed tomography revealed heterogeneous and irregular minimal contrast enhancement in the pelvic ectopic kidney parenchyma. Radiologists reported that the images were consistent with chronic pyelonephritis. A Tc-99m dimercaptosuccinic acid renal scan demonstrated a nonfunctioning right pelvic ectopic kidney. The patient underwent open simple nephrectomy via modified Gibson incision. The whole mass was a distended, saclike structure without any grossly visible renal tissue. Pathological examination showed renal pelvis squamous cell carcinoma 8 cm in diameter infiltrating into the renal capsule and perinephritic fatty tissue. The patient was staged as T4N0M1 renal pelvis squamous cell carcinoma. The patient was being treated in the intensive care unit for respiratory distress on the seventh day after the operation. By the first-month follow-up visit, the patient had died of acute respiratory distress syndrome. Conclusions: Although rare, renal pelvis squamous cell carcinoma should be considered in the differential diagnosis of a renal mass in patients who have renal anomalies and chronic pyelonephritis.
    [Show full text]
  • Application of Percutaneous Osteoplasty in Treating Pelvic Bone Metastases: Efficacy and Safety
    Cardiovasc Intervent Radiol (2019) 42:1738–1744 https://doi.org/10.1007/s00270-019-02320-8 CLINICAL INVESTIGATION NON-VASCULAR INTERVENTIONS Application of Percutaneous Osteoplasty in Treating Pelvic Bone Metastases: Efficacy and Safety 1 1 1 1 1 He-Fei Liu • Chun-Gen Wu • Qing-Hua Tian • Tao Wang • Fei Yi Received: 17 October 2018 / Accepted: 20 August 2019 / Published online: 23 September 2019 Ó Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2019 Abstract 1.87 ± 1.46 at 6 months (P \ 0.05), 1.90 ± 1.47 at Background Percutaneous vertebroplasty has been a good 9 months (P \ 0.05), and 1.49 ± 1.17 at 12 months option to treat vertebral metastases. The pelvic bone is a (P \ 0.05). The ODI also changed after the procedure, common site of spread for many cancers. Using follow-up with significant differences between baseline scores and at data for 126 patients, we evaluated the safety and efficacy each follow-up examination (P \ 0.05). Pain relief was of percutaneous osteoplasty (POP) to treat pelvic bone achieved in 118 patients (93.65%); however, pain relief metastases. was not obvious in seven patients (5.56%), and pain was Materials and Methods In this retrospective study, 126 aggravated in one patient (0.79%). Extraosseous cement patients (mean age 57.45 ± 11.46 years old) with 178 leakage occurred in 35 patients (27.78%) without causing lesions were treated using POP. The visual analog scale any clinical complications. (VAS), Oswestry Disability Index (ODI), and the changes Conclusion Percutaneous osteoplasty is a safe and effec- in the patient’s use of painkillers were used to evaluate pain tive choice for patients with painful osteolytic pelvic bone and quality of life before the procedure, and at 3 days and metastases.
    [Show full text]
  • A Case of Incidental Schwannoma Mimicking Necrotic Metastatic Lymph Node from Bladder Cancer
    medicina Case Report A Case of Incidental Schwannoma Mimicking Necrotic Metastatic Lymph Node from Bladder Cancer Jeong-Hyouk Choi 1, Koo-Han Yoo 1 , Dong-Gi Lee 1, Gyeong-Eun Min 1 , Gou-Young Kim 2 and Tae-Soo Choi 1,* 1 Department of Urology, College of Medicine, Kyung Hee University, Seoul 05278, Korea; [email protected] (J.-H.C.); [email protected] (K.-H.Y.); [email protected] (D.-G.L.); [email protected] (G.-E.M.) 2 Department of Pathology, College of Medicine, Kyung Hee University, Seoul 05278, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-440-6271; Fax: +82-2-440-7744 Abstract: Background and Objectives: Retroperitoneal schwannoma is a very rare case of schwan- noma which commonly occurs in the other part of the body. However, it is difficult to distinguish schwannoma from other tumors before pathological examination because they do not show specific characteristics on imaging study such as ultrasound, computed tomography (CT), and magnetic reso- nance image (MRI). Case summary: A 60-year-old male showed a retroperitoneal cystic tumor which is found incidentally during evaluation of coexisted bladder tumor. Neurogenic tumor was suspicious for the retroperitoneal tumor through pre-operative imaging study. Finally, a schwannoma was diagnosed by immunohistochemical examination after complete surgical excision laparoscopically. Conclusion: As imaging technology is developed, there may be more chances to differentiate schwan- Citation: Choi, J.-H.; Yoo, K.-H.; Lee, noma from other neoplasm. However, still surgical resection and histopathological examination is D.-G.; Min, G.-E.; Kim, G.-Y.; Choi, feasible for diagnosis of schwannoma.
    [Show full text]
  • SNOMED CT Codes for Gynaecological Neoplasms
    SNOMED CT codes for gynaecological neoplasms Authors: Brian Rous1 and Naveena Singh2 1Cambridge University Hospitals NHS Trust and 2Barts Health NHS Trusts Background (summarised from NHS Digital): • SNOMED CT is a structured clinical vocabulary for use in an electronic health record. It forms an integral part of the electronic care record, and serves to represent care information in a clear, consistent, and comprehensive manner. • The move to a single terminology, SNOMED CT, for the direct management of care of an individual, across all care settings in England, is recommended by the National Information Board (NIB), in “Personalised Health and Care 2020: A Framework for Action”. • SNOMED CT is owned, managed and licensed by SNOMED International. NHS Digital is the UK Member's National Release Centre for the creation of, and delegated authority to licence the SNOMED CT Edition and derivatives. • The benefits of using SNOMED CT in electronic care records are that it: • enables sharing of vital information consistently within and across health and care settings • allows comprehensive coverage and greater depth of details and content for all clinical specialities and professionals • includes diagnosis and procedures, symptoms, family history, allergies, assessment tools, observations, devices • supports clinical decision making • facilitates analysis to support clinical audit and research • reduces risk of misinterpretations of the record in different care settings • Implementation plans for England: • SNOMED CT must be implemented across primary care and deployed to GP practices in a phased approach from April 2018. • Secondary care, acute care, mental health, community systems, dentistry and other systems used in direct patient care must use SNOMED CT as the clinical terminology, before 1 April 2020.
    [Show full text]